Trial Profile

Expanded Access of Anti-CD3/CD7 Immunotoxin Combination (T-Guard) for the Treatment of Steroid-Refractory Acute Graft versus host disease

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 13 Dec 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti-CD3-ricin chain A conjugate/anti-CD7-ricin chain A conjugate (Primary)
Indications Graft-versus-host disease
Focus Expanded access; Therapeutic Use

Most Recent Events

13 Dec 2019 New trial record
10 Dec 2019 Results of expanded access program of Anti-CD3/CD7 immunotoxin combination for the treatment of steroid-refractory acute Gvhd has presented at the 61st Annual Meeting and Exposition of the American Society of Hematology
09 Dec 2019 Results presented in a Xenikos Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com